For glioma cells with IDH mutations, targeting mutant IDH can restore the release of CXCL10 and inhibit the production of PD-L1, promoting recruitment and tumor recognition of CTLs and inhibiting Tregs. The gene discussed is CD274; the disease is central nervous system cancer.